Excelsior Sciences, a small-molecule discovery biotech, launched Wednesday with a $70 million Series A.
Why it matters: Excelsior is in "active conversations" with potential biotech and pharma partners to develop therapeutics, CEO Michael Foley tells Axios Pro.
